Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settingsT. M. A. Abdel-Fatah, Stephen Chan, P. Dickinson et al.|Annals of Oncology|2013Cited by 88